Addicted to proteostasis: How KRAS-driven cancers acquire resistance to clinical KRAS inhibitors

被引：0
|
作者：
Klein, Austin T. [1 ,2 ,3 ]
Mendillo, Marc L. [1 ,2 ,3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Dept Biochem & Mol Genet, Chicago, IL 60611 USA
[2] Northwestern Univ, Simpson Querrey Ctr Epigenet, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
CELL CHEMICAL BIOLOGY | 2023年 / 30卷 / 11期
关键词：
D O I：
10.1016/j.chembiol.2023.10.007
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The development of KRAS inhibitors was a remarkable feat, yet their efficacy is limited by inevitable resis-tance. In the September issue of Science, Lv et al.1 demonstrate how KRAS-driven cancers rewire signaling to restore protein homeostasis and acquire resistance to KRAS inhibitors with implications for novel combi-nation therapeutic strategies.
引用
收藏
页码：1334 / 1336
页数：3
相关论文
共 50 条
  • [21] Rewired proteostasis in KRAS inhibitor resistance
    Eccleston, Alex
    NATURE REVIEWS DRUG DISCOVERY, 2023, 22 (11) : 871 - 871
  • [22] From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
    Mahsa Saliani
    Razieh Jalal
    Mohammad Reza Ahmadian
    Cancer Biology & Medicine, 2019, (03) : 435 - 461
  • [23] From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers
    Mahsa Saliani
    Razieh Jalal
    Mohammad Reza Ahmadian
    Cancer Biology & Medicine, 2019, 16 (03) : 435 - 461
  • [24] Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors
    Lv, Xiangdong
    Lu, Xuan
    Cao, Jin
    Luo, Qin
    Ding, Yao
    Peng, Fanglue
    Pataer, Apar
    Lu, Dong
    Han, Dong
    Malmberg, Eric
    Chan, Doug W.
    Wang, Xiaoran
    Savage, Sara R.
    Mao, Sufeng
    Yu, Jingjing
    Peng, Fei
    Yan, Liang
    Meng, Huan
    Maneix, Laure
    Han, Yumin
    Chen, Yiwen
    Yao, Wantong
    Chang, Eric C.
    Catic, Andre
    Lin, Xia
    Miles, George
    Huang, Pengxiang
    Sun, Zheng
    Burt, Bryan
    Wang, Huamin
    Wang, Jin
    Yao, Qizhi Cathy
    Zhang, Bing
    Roth, Jack A.
    O'Malley, Bert W.
    Ellis, Matthew J.
    Rimawi, Mothaffar F.
    Ying, Haoqiang
    Chen, Xi
    SCIENCE, 2023, 381 (6662) : 1065 - +
  • [25] Could Drug Delivery Systems Be Enhancers for Therapy against KRAS-driven Cancers?
    R. R. Khusnutdinov
    Reviews and Advances in Chemistry, 2024, 14 (4): : 273 - 304
  • [26] Immunoprevention of KRAS-driven lung adenocarcinoma by a multi-peptide KRAS vaccine
    Pan, Jing
    Zhang, Qi
    Sei, Shizuko
    Shoemaker, Robert H.
    Lubet, Ronald A.
    Wang, Yian
    You, Ming
    CANCER RESEARCH, 2017, 77
  • [27] Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
    Ali, Moiez
    Kaltenbrun, Erin
    Anderson, Grace R.
    Stephens, Sarah Jo
    Arena, Sabrina
    Bardelli, Alberto
    Counter, Christopher M.
    Wood, Kris C.
    NATURE COMMUNICATIONS, 2017, 8
  • [28] Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
    Moiez Ali
    Erin Kaltenbrun
    Gray R. Anderson
    Sarah Jo Stephens
    Sabrina Arena
    Alberto Bardelli
    Christopher M. Counter
    Kris C. Wood
    Nature Communications, 8
  • [29] KRAS-driven ROS promote malignant transformation
    Suh, Yongjoon
    Lee, Su-Jae
    MOLECULAR & CELLULAR ONCOLOGY, 2015, 2 (01):
  • [30] The Key Role of Calmodulin in KRAS-Driven Adenocarcinomas
    Nussinov, Ruth
    Muratcioglu, Serena
    Tsai, Chung-Jung
    Jang, Hyunbum
    Gursoy, Attila
    Keskin, Ozlem
    MOLECULAR CANCER RESEARCH, 2015, 13 (09) : 1265 - 1273
12345